Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine, Hiroshima 734, Japan (Received for publication January 18, 1990) Whentumor cells are chronically treated with antitumor drugs such as vinca alkaloids or anthracyclines, they often acquire resistance not only to the same drugs but also to other antitumor drugs1~3). Although the mechanism of this pleiotropic drug resistance is not fully understood, decreased uptake and retention of doxorubicin ( = adriamycin, ADM) and daunorubicin ( = daunomycin, DNR) in drug resistant cell lines induced by ADM in mouseleukemia P388 cells and mouse lymphoblastoma L5178Y cells have been reported4 '5) . Inaba et al.5) observed the enhanced active transport of drugs outward plasma membrane in ADM-resistant P388 cells (P388/ADM). Sugimo to et al. 6 ) also proposed that the alteration in plasma membrane of ADM-resistant L5178Y cells (L5 1 78Y/ADM)might be responsible for their lower sensitivity to antitumor drugs. Besides the membrane alteration, cytoplasmic functions were closely related to drug resistance. As compared to parental P388 cells (P388/S), P388/ADMshowed a decreased content of cytochrome P-450 linked microsomal mixed-function oxidase components7), with which the metabolism of antitumor drugs seems to be deeply associated.
In a search for anthracyclines which are able to overcome drug resistance or highly toxic even to ADM-resistant cells, a total of 37 anthracyclines, including ADM (1) Nishimura et al.4) . The resistance factors for L5178Y/ADM ranged from 0.5 against (7i?,9i?)-4-demethyl-1 1 -deoxy-iV-trifluoroacetyldaunomycin (37) to 23,000 against 4-Odemethyl-6-deoxyadriamycin (12) . Anthracyclines, to which L5178Y/ ADM shows much higher resistance than to ADM or DNR, are potent inhibitors of L5178Y/S but not of L5178Y/ADMwith the exception of 3'-deamino- 6) . Though there exists significant difference in a range of distribution, the resistance factors for P388/ADM and L5178Y/ADM are apt to be proportionate to one another excluding the case of MRA-CN, as shown in Fig The N-trifluoroacetyl derivatives of daunorubicin, i.e., 23, 29 and 32, inhibited the growth of P388/S significantly, but these compounds are not necessarily potent inhibitors of L5178Y/S as was proven by the results for 29 and 32. The ID50 of MRA-CN against L5178Y/ADM was as low as 7 x 10~6/xg/ml, in a marked contrast to those for the other anthracyclines (0.07 jHg/ml or more). The resistance factor for L5178Y/ADMagainst MRACNwas nevertheless 20-times higher than that This suggests that the cyano-morpholinyl group may act as an alkylating moiety like the a-cyanoamine groups carried by the antibiotics with alkylating potential such as saframycin A1 5~17), cyanocycline A18), naphthocyanidine19) and cyanonaphthyridomycin20>21). A putative mechanism for covalent alkylation of DNAby MRA-CNmay account for pronounced antitumor activity of this compound as compared with that of MRA. Cross resistance of P388/ADM was related to the specific classes based on mechanismof action rather than to chemical nature. The best example of this is the complete resistance of P388/ADM to emetine as compared to the sensitivity of P388/ADMto emetine mustard22). The substitution of the tetrahydroisoquinoline nitrogen of emetine with the alkylating moiety renders the derivatives inactive as an inhibitor of protein synthesis and results in an alkylating agent. A subline of human ovarian carcinoma ES-2 was developed with a 10-fold resistance to MRA-CN23). This subline ES-2/MR was highly cross resistant to the alkylating agents melphalan and carmustine but relatively sensitive to ADMand vinblastine. It is possible that alkylating agents do not share the effluxtransmembrane mechanism which functions for DNAintercalators, vinca alkaloids and protein synthesis inhibitors.
Alternatively, the rapid reaction of alkylating agents with DNAdoes not require the extended period of intracellular drug content. Dueto either one of these two mechanismor both, MRA-CN can overcome the drug resistance of P388/ADMwhich is probably as sensitive to alkylating agents as P388/S. The extremely low ID5Os of MRA-CNfor both L5178Y/S and L5178Y/ADM could also be accounted for by its increased lipophilicity and alkylating ability.
On going from ADM to MRA-CN, however, the resistance factor for L5178Y/ADMincreased from 31 to 730. Although the poor drug uptake for certain antitumor agents by L5 1 78Y/ADM (owing to decreased influx), which has been reported to be the basis of its resistance to anthracyclines4j6), could be nullified by the lipophilicity of MRA-CN as in the case of P388/ADM, the persistent resistance to MRA-CN might result from its potential resistance to alkylating agents. This proposed additional mechanism for the drug resistance of L5178Y/ADM is now under investigation in our laboratory.
